4-Aminoethylamino-emodin - a novel potent inhibitor of GSK-3β- acts as an insulin-sensitizer avoiding downstream effects of activated β-catenin

Glycogen synthase kinase-3β, or a link between amyloid and tau pathology?

(2010) D. Muyllaert et al.   GENES BRAIN AND BEHAVIOR

Enhanced glycogenesis is involved in cellular senescence via GSK3/GS modulation

(2008) Yong-Hak Seo et al.   AGING CELL

Inhibition of GSK3 differentially modulates NF-κB, CREB, AP-1 and β-catenin signaling in hepatocytes, but fails to promote TNF-α-induced apoptosis

(2008) Frank Götschel et al.   EXPERIMENTAL CELL RESEARCH

Preclinical efficacy on GSK-3 inhibitors: Towards a future generation of powerful drugs

(2008) Ana Martinez   MEDICINAL RESEARCH REVIEWS

Correlation between β-catenin mutations and expression of Wnt-signaling target genes in hepatocellular carcinoma

(2008) Madeleine Austinat et al.   Molecular Cancer

Novel 9-oxo-thiazolo[5,4-f]quinazoline-2-carbonitrile derivatives as dual cyclin-dependent kinase 1 (CDK1)/glycogen synthase kinase-3 (GSK-3) inhibitors: Synthesis, biological evaluation and molecular modeling studies

(2007) Cédric Logé et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY